Kiffik Biomedical Inc.

Kiffik Biomedical Inc. , based in the US, focuses on innovative biomarker diagnostics through its advanced KIFFIK EXP™ platform, enabling continuous monitoring via a non-invasive wearable device. Founded in 2021 and headquartered in Providence, US, Kiffik Biomedical Inc. specializes in developing real-time biomarker diagnostics.

The company has made strategic pivots to enhance its operational capabilities since inception. The founder has a history of innovation in the healthcare sector, although specific prior ventures are not detailed. Kiffik Biomedical Inc. specializes in the development of its flagship product, the KIFFIK EXP™ platform, which enables real-time biomarker diagnostics through continuous monitoring of interstitial fluid (ISF) via a non-invasive wearable device.

This innovative technology captures a diverse array of molecular signals, including unique biomarkers not present in plasma, thereby providing critical insights into drug efficacy and immune activity at the tissue level. The platform addresses various healthcare challenges, such as real-time ovulation tracking, hormone monitoring in menopause, early detection of traumatic brain injuries, and the identification of inflammatory conditions. Kiffik serves a broad clientele, including healthcare providers, pharmaceutical companies, and research institutions, with applications spanning emergency medicine, oncology, dermatology, and chronic disease management. The products are marketed in several geographical regions, specifically targeting North America and Europe, where there is a significant demand for advanced diagnostic tools in both clinical and research settings.

Kiffik Biomedical Inc. generates revenue through strategic partnerships and direct transactions with its clients in the healthcare and pharmaceutical sectors. The transaction structure primarily involves B2B relationships, where healthcare facilities and clinical researchers utilize the KIFFIK EXP™ platform for real-time biomarker monitoring in various applications. Clients may enter into subscription agreements for ongoing access to the platform's diagnostic capabilities or purchase specific services tailored to their needs, such as companion diagnostics and biomarker discovery.

These client engagements facilitate the provision of continuous data, enhancing the decision-making processes in clinical trials and patient care. While specific pricing details for individual services or subscription plans are not disclosed, the business model emphasizes the platform's scalability and adaptability to meet diverse therapeutic requirements across multiple sectors, reinforcing Kiffik's position as a leader in real-time diagnostic innovation. Kiffik Biomedical has completed two funding rounds, recently raised USD 20 million in series A funding led by new investor Section 32, with participation from other new investors Aperture Venture Capital, BrightEdge Ventures and SteelSky Ventures, in December 2025. The company intends to utilize this funding to expand its platform, advance clinical programs, accelerate manufacturing scale-up, and achieve regulatory readiness.

Kiffik plans to introduce new products designed to enhance its diagnostic capabilities and aims to expand into new markets, specifically targeting regions beyond North America and Europe, by 2026.